lopinavir has been researched along with Multiple Myeloma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, R; Chan, H; Elinder-Camburn, A; Hanna, M; Henderson, R; Merriman, E; Simpson, D | 1 |
| Bader, J; Besse, A; Besse, L; Driessen, C; Kraus, M; Morgan, GJ; Overkleeft, HS; Rasche, L; Stolze, SC; Weinhold, N | 1 |
2 other study(ies) available for lopinavir and Multiple Myeloma
| Article | Year |
|---|---|
The addition of lopinavir-ritonavir to carfilzomib-based triplets can induce meaningful clinical response in carfilzomib-refractory myeloma patients: a single-center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lopinavir; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Ritonavir | 2022 |
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; HIV Protease Inhibitors; Humans; Lopinavir; Multiple Myeloma; Nelfinavir; Oligopeptides; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors | 2018 |